-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Novavax announced in its UK- based Phase III trial that its COVID-19 vaccine NVX-CoV2373 is 96.
COVID-19
This study recruited more than 15,000 18-84-year-old subjects, of which 27% were older than 65 years old.
In addition to the final efficacy analysis of the original COVID-19 strain, Novavax also found that NVX-CoV2373 is 86.
Stanley Erck, President and CEO of Novavax, said: "The data show that NVX-CoV2373 provides complete protection against the most serious diseases.
Original source:
Original source:http:// href="http://" target="_blank" rel="noopener">http:// style="vertical-align: inherit;"> http:// Leave a message here